FibroBiologics to Present at the BIO Investment & Growth Summit
FibroBiologics (Nasdaq: FBLG) announced its Founder and CEO, Pete O’Heeron, will present at the BIO Investment & Growth Summit March 2-3, 2026, at Eden Roc, Miami Beach.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG) announced its Founder and CEO, Pete O’Heeron, will present at the BIO Investment & Growth Summit March 2-3, 2026, at Eden Roc, Miami Beach. The company presentation is scheduled for 10:15 a.m. ET on Monday, March 2, and management will hold one-on-one meetings during the event.
Investors can obtain more information via the company website or by contacting info@fibrobiologics.com; social channels include LinkedIn, YouTube, Facebook and X.
Details
News Market Reaction – FBLG
On Feb 26, the day this news came out, FBLG closed 7.44% above the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
Key Figures
- Patents portfolio
- 270+ patents
- Issued and pending, as described in company overview
- Summit dates
- March 2–3, 2026
- BIO Investment & Growth Summit schedule
- Presentation time
- 10:15 a.m. ET
- Company presentation slot on March 2, 2026
Historical Context
-
Full-year 2025 results and pipeline plus financing and debt update.
-
Nasdaq Hearings Panel grants extension to regain listing compliance.
-
CEO selected to present at A4LI H-SPAN Summit main stage.
-
Canadian patent granted for fibroblast-based cachexia treatment platform.
-
CEO to present at DealFlow Discovery Conference and meet investors.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
fibroblasts medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the BIO Investment & Growth Summit taking place March 2-3, 2026, at the Eden Roc in Miami Beach, FL.
FibroBiologics will deliver a company presentation at 10:15 a.m. ET on Monday, March 2 and will be available for one-on-one meetings throughout the event.
For more information, please visit FibroBiologics’ website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.